Liver Metastases Imaging: CT vs. MRI: Which Detects More?
Your cancer staging scan found liver lesions—are these metastases? Accurate liver imaging dramatically changes cancer staging, treatment options, and prognosis. CT scan detects most liver metastases and is the first-line test for most patients. MRI with hepatocyte-specific contrast detects smaller lesions, characterizes indeterminate nodules, and is essential for liver-directed therapy planning. Understanding when each test is indicated ensures accurate staging and appropriate treatment.
Quick Answer: CT First, MRI for Problem-Solving
Contrast-enhanced CT (portovenous phase) is the first-line imaging test for detecting liver metastases in most patients. CT accurately detects metastases >1 cm with sensitivity >80%, provides whole-body staging in a single exam, and is widely available.
MRI with liver-specific contrast (gadoxetate or gadoxetate disodium) is indicated for:
- Small lesion detection (＜1 cm): Superior sensitivity for metastases 5-10 mm
- Indeterminate CT lesions: Characterize as metastasis vs. benign hemangioma, cyst, focal nodular hyperplasia
- Liver-directed therapy planning: Precise mapping for ablation, embolization, stereotactic radiation
- Primary liver tumors: HCC, cholangiocarcinoma characterization
- High-risk patients: Colon cancer, breast cancer, neuroendocrine tumors (high prevalence of liver mets)
”Clinical Guideline: The American College of Radiology gives CT a rating of "8" (usually appropriate) for initial staging of suspected liver metastases. MRI receives a rating of "8" as well (usually appropriate) and is specifically recommended when CT is equivocal or for preoperative planning.
Source: ACR Appropriateness Criteria®® - Liver Metastases Date: 2023
Understanding Liver Metastases
Epidemiology and Common Primaries
Primary Cancers that Metastasize to Liver:
| Primary Cancer | % with Liver Mets at Diagnosis | Pattern | MRI Advantage |
|---|---|---|---|
| Colorectal cancer | 15-25% | Hypovascular | Better detection |
| Breast cancer | 5-10% | Variable (hypo- or hypervascular) | Characterization |
| Pancreatic cancer | 30-50% | Hypovascular | Small lesion detection |
| Lung cancer | 20-40% | Hypervascular | Detection |
| Neuroendocrine tumors | 40-90% | Hypervascular | Detection, characterization |
| Gastric cancer | 10-20% | Hypovascular | Detection |
| Melanoma | 10-20% | Variable | Characterization |
| Ovarian cancer | 5-10% | Variable | Characterization |
”Clinical Insight: Colorectal cancer is the most common cause of liver metastases in developed countries. Up to 50% of colorectal cancer patients develop liver metastases, and liver is the only site of metastasis in 20-30%—making accurate liver imaging critical for potential curative resection.
Source: Annals of Surgical Oncology - Liver Metastases from Colorectal Cancer: Epidemiology and Management Date: 2022
Why Liver Metastasis Detection Matters
Impact on Staging and Treatment:
| Scenario | Imaging Implications | Treatment Impact |
|---|---|---|
| No liver mets | Early-stage disease | Curative surgery, systemic therapy |
| Resectable liver mets | Limited number, favorable location | Metastasectomy (curative intent) |
| Unresectable liver mets | Numerous, diffuse, or critical location | Systemic therapy, liver-directed therapy (TACE, ablation) |
| Indeterminate lesions | Can't characterize | MRI for diagnosis, may change management |
”Clinical Reality: In colorectal cancer, finding liver metastases changes management from curative primary tumor resection to either combined liver resection (curative) or systemic palliation. Accurate detection is critical—missing liver mets denies patients curative-intent surgery.
Source: British Journal of Surgery - Impact of Liver Metastasis Detection on Management of Colorectal Cancer Date: 2021
CT Scan for Liver Metastases
CT Protocol for Liver Metastases
Multiphasic Liver CT Protocol:
| Phase | Timing | What It Shows |
|---|---|---|
| Non-contrast (optional) | Before contrast | Detect calcifications, hemorrhage, fat |
| Late arterial phase | 35-40 seconds after contrast | Hypervascular metastases (neuroendocrine, renal, melanoma, breast, thyroid) |
| Portal venous phase | 70-80 seconds after contrast | Hypovascular metastases (colon, pancreatic, gastric), most liver mets seen here |
| Delayed phase (optional) | 3-5 minutes | Some lesions better seen, washout characteristics |
What CT Shows:
- Size and number: Number of lesions, size measurement for response assessment
- Location: Segmental anatomy for surgical planning
- Enhancement pattern: Hypovascular (most common) vs. hypervascular
- Morphology: Round, well-circumscribed lesions
- Extrahepatic disease: Lymph nodes, peritoneal implants, primary tumor
CT Findings in Liver Metastases
Typical Appearance:
| Feature | Hypovascular Mets (most common) | Hypervascular Mets (less common) |
|---|---|---|
| Primary cancers | Colon, pancreas, stomach, lung | Neuroendocrine, renal cell, melanoma, breast, thyroid |
| Arterial phase | Hypoenhancing (darker than liver) | Hyperenhancing (brighter than liver) |
| Portal phase | Hypoenhancing (classic appearance) | Iso- or hyperenhancing (may wash out) |
| Morphology | Round, well-defined, often multiple | Round, well-defined, often multiple |
| Size | Detect >1 cm reliably | Detect >0.5 cm reliably |
| Associated findings | Possible liver capsule retraction | Possible transient hepatic attenuation difference (THAD) |
”Key Point: Portal venous phase is the most important phase for detecting hypovascular metastases (most common). Hypervascular metastases are best seen in late arterial phase and may become isodense (invisible) in portal phase.
Source: Radiographics - CT of Liver Metastases: Protocol and Interpretation Date: 2021
CT Diagnostic Accuracy
Sensitivity by Lesion Size:
| Lesion Size | CT Sensitivity | Clinical Implications |
|---|---|---|
| ＜5 mm | 30-50% | Often missed, may require MRI |
| 5-10 mm | 50-70% | Detection improves, MRI superior |
| 10-20 mm | 80-90% | Good detection, CT usually sufficient |
| >20 mm | >95% | Excellent detection |
CT Advantages:
- ✅ Widely available, faster (5-10 minutes)
- ✅ Whole-body staging (liver + primary + rest of body)
- ✅ Good for >1 cm lesions (sensitivity 80-90%)
- ✅ Lower cost than MRI
- ✅ Better for patients with MRI contraindications
CT Limitations:
- ❌ Lower sensitivity for small lesions (＜1 cm)
- ❌ Radiation exposure (10-15 mSv for multiphasic)
- ❌ Iodinated contrast (kidney function, allergy)
- ❌ Limited characterization of indeterminate lesions
”Clinical Evidence: In colorectal cancer patients, CT misses 20-30% of liver metastases detected by MRI, particularly lesions ＜1 cm. This missed detection rate changes surgical management in 10-15% of patients.
Source: European Journal of Radiology - CT vs. MRI for Liver Metastasis Detection in Colorectal Cancer Date: 2022
MRI for Liver Metastases
MRI Protocol Advantages
Liver MRI Protocol:
| Sequence | What It Shows | Advantage |
|---|---|---|
| T1-weighted in-phase and opposed-phase | Liver fat, hemorrhage, iron | Characterize lesions |
| T2-weighted fat-suppressed | Edema, cysts, hemangiomas | Lesion characterization |
| Diffusion-weighted imaging (DWI) | Cellularity (restricts diffusion) | Detect small metastases, distinguish benign vs. malignant |
| Dynamic contrast-enhanced (arterial, portal, delayed) | Enhancement pattern | Characterize lesions |
| Hepatocyte-specific phase (20 minutes) | Lesions contain functioning hepatocytes | Distinguish FNH, adenoma, HCC from metastasis |
Hepatocyte-Specific Contrast Agents:
- Gadoxetate disodium (Eovist/Primovist): 50% excreted by biliary system, 50% renal
- Gadoxobenate dimeglumine (MultiHance): Similar dual excretion
- Mechanism: Taken up by functioning hepatocytes via OATP transporters
- Hepatocyte phase (20 minutes): Lesions with hepatocytes (FNH, adenoma, HCC) enhance; metastases (no hepatocytes) appear dark
”Technical Advantage: Hepatocyte-specific contrast provides unique information unavailable on CT—lesions that take up contrast have functioning hepatocytes (benign or HCC), while metastases (no hepatocytes) appear dark against enhancing liver. This dramatically improves characterization.
Source: Radiographics - Liver MRI: Hepatocyte-Specific Contrast Agents Date: 2022
MRI Findings in Liver Metastases
Typical MRI Appearance:
| Sequence | Metastasis Appearance | Benign Mimickers |
|---|---|---|
| T1-weighted | Hypointense (dark) relative to liver | Hemangioma: very dark; Cyst: very dark; FNH: isointense |
| T2-weighted | Hyperintense (bright) relative to liver | Hemangioma: very bright ("lightbulb"); Cyst: very bright; FNH: mildly bright |
| DWI/ADC | Restricted diffusion (bright DWI, dark ADC) | Cyst, hemangioma: no restriction (dark DWI, bright ADC) |
| Arterial phase | Variable (hypo-, iso-, or hyperenhancing) | Hemangioma: peripheral nodular enhancement; FNH: intense homogeneous enhancement |
| Portal phase | Hypoenhancing (dark) with peripheral washout | Hemangioma: centripetal fill-in; FNH: iso- or hyperenhancing |
| Hepatocyte phase | Hypointense (dark)—no hepatocytes | FNH, adenoma: hyperintense (bright)—contain hepatocytes |
Characterization Features:
- Metastasis: T1 dark, T2 bright, DWI restricted, portal phase hypoenhancing, hepatocyte phase dark
- Hemangioma: T1 dark, T2 very bright, DWI no restriction, peripheral nodular enhancement with centripetal fill-in
- Cyst: T1 dark, T2 very bright, DWI no restriction, no enhancement
- Focal nodular hyperplasia (FNH): T1 iso- or mildly hypointense, T2 mildly bright, intense arterial enhancement, hepatocyte phase hyperintense (contains hepatocytes)
”Diagnostic Power: Hepatocyte phase imaging is the key discriminator. Metastases appear dark (no hepatocytes) while FNH, adenoma, and HCC appear bright (contain hepatocytes). This single finding can characterize many indeterminate lesions seen on CT.
Source: Journal of Magnetic Resonance Imaging - Hepatocyte-Specific Contrast for Liver Lesion Characterization Date: 2023
MRI Diagnostic Accuracy
Sensitivity by Lesion Size:
| Lesion Size | MRI Sensitivity | Clinical Implications |
|---|---|---|
| ＜5 mm | 70-80% | Superior to CT (30-50%) |
| 5-10 mm | 80-90% | Superior to CT (50-70%) |
| 10-20 mm | >95% | Similar to CT, but better characterization |
| >20 mm | >98% | Similar to CT |
MRI Advantages:
- ✅ Superior sensitivity for small lesions (＜1 cm)
- ✅ Superior characterization of indeterminate lesions
- ✅ No radiation (safe for serial imaging)
- ✅ Diffusion-weighted imaging detects occult metastases
- ✅ Hepatocyte phase distinguishes metastases from benign hepatocyte-containing lesions
MRI Limitations:
- ❌ Longer scan time (30-45 minutes)
- ❌ Higher cost ($800-2,000 vs. $500-1,500 for CT)
- ❌ Limited availability (not all centers have hepatocyte-specific contrast)
- ❌ Contraindications (certain implants, severe claustrophobia)
- ❌ Gadolinium contrast concerns (NSF in severe kidney disease)
”Clinical Impact: In colorectal cancer patients being considered for curative liver resection, MRI changes surgical management in 20-30% of cases compared to CT alone—either by finding additional metastases (contraindicating surgery) or characterizing indeterminate lesions as benign (allowing surgery).
Source: Annals of Surgery - Impact of Liver MRI on Surgical Management of Colorectal Liver Metastases Date: 2021
CT vs. MRI: Choosing the Right Test
When CT Is Sufficient
CT-Only Approach (adequate for most patients):
- Initial staging: Most cancers with low prevalence of small liver mets
- Treatment response: Monitoring known metastases on systemic therapy
- No liver-directed therapy planned: Systemic therapy only
- Large metastases (>2 cm): CT detection excellent
- MRI contraindicated: Pacemakers, severe claustrophobia
Appropriate for:
- Initial staging of most cancers (lung, breast, pancreatic, gastric)
- Follow-up of known liver mets on systemic therapy
- Emergency settings: Rapid assessment needed
- Patients with implants: MRI contraindicated
”Clinical Practice: For most patients with cancer, CT alone is adequate for liver staging. CT provides accurate detection of metastases >1 cm and simultaneously stages the primary tumor, lymph nodes, and rest of body.
Source: American Journal of Roentgenology - CT for Liver Metastasis Detection: Current Practice Date: 2022
When MRI Is Essential
MRI Indications (adds value beyond CT):
- Small lesion detection: High-risk primaries (colon, breast, neuroendocrine) where detecting 5-10 mm mets changes management
- Indeterminate CT lesions: Cannot characterize as metastasis vs. benign
- Liver-directed therapy planning: Ablation, TACE, stereotactic body radiation therapy (SBRT) requires precise mapping
- Primary liver tumors: HCC characterization, cholangiocarcinoma detection
- Surgical planning: Curative liver resection or metastasectomy planning
- Problem-solving: Equivocal CT findings
- High-risk patients: Strong family history, known aggressive tumor biology
”High-Value Scenarios: In colorectal cancer being considered for liver metastasectomy, breast cancer with indeterminate liver lesions, and neuroendocrine tumors (often hypervascular and numerous), MRI is essential and changes management in 20-30% of cases.
Source: Radiology - MRI for Liver Metastases: Indications and Impact on Patient Management Date: 2023
Decision Guide
Primary Cancer-Specific Approach:
| Primary Cancer | Initial Imaging | Add MRI If... |
|---|---|---|
| Colorectal | CT with liver protocol | Surgical candidate; indeterminate lesions; high risk of small mets |
| Breast | CT with liver protocol | Indeterminate lesions; surgical candidate; HER2+ (hypervascular mets) |
| Pancreatic | CT with liver protocol | Surgical candidate; indeterminate lesions |
| Lung | CT (chest/abdomen/pelvis) | Indeterminate lesions; surgical candidate |
| Neuroendocrine | CT + MRI (both initially) | High prevalence of small, hypervascular mets |
| Melanoma | CT + consider MRI | Indeterminate lesions; high risk of small mets |
| Ovarian | CT + consider MRI | Indeterminate lesions; surgical candidate |
”Key Concept: Surgical candidacy is the most important factor determining whether MRI adds value. If liver metastases are potentially resectable (curative intent), MRI is essential to ensure accurate staging. If systemic therapy only is planned (palliative), CT alone is usually sufficient.
Source: Annals of Surgical Oncology - Liver Imaging in Patients with Potentially Resectable Liver Metastases Date: 2022
Liver-Directed Therapy Planning
When Precision Matters
Liver-Directed Therapies requiring precise imaging:
| Therapy | Imaging Requirements | Why MRI Essential |
|---|---|---|
| Thermal ablation (RFA, MWA, cryoablation) | Exact lesion size, location, relationship to vessels | Detects small mets adjacent to target lesion |
| Transarterial chemoembolization (TACE) | Tumor vascularity, portal vein patency | Identifies hypervascular mets, vascular mapping |
| Stereotactic body radiation (SBRT) | Precise lesion delineation, respiratory motion | Identifies all lesions for treatment planning |
| Selective internal radiation therapy (SIRT/Y90) | Tumor vascularity, shunt assessment | Identifies hypervascular mets, vascular mapping |
| Surgical resection | Exact number, size, location of mets | Detects small mets CT misses |
| Hepatic artery infusion pump | Liver-only disease, exact tumor burden | Ensures no extrahepatic disease, small mets |
”Surgical Reality: For curative liver resection or metastasectomy, missing even a single 5 mm metastasis can lead to early recurrence and prevent cure. MRI's superior sensitivity for small lesions is essential in this scenario.
Source: Journal of Clinical Oncology - Impact of Preoperative MRI on Outcomes After Liver Resection for Metastases Date: 2023
Special Populations
Fatty Liver: Detection Challenges
Challenges:
- Steatosis (fatty liver): Liver becomes brighter on T1, reducing lesion conspicuity
- CT: Fatty liver attenuation may match hypovascular metastases, reducing detection
- MRI: T1-weighted imaging less affected, but fat may confound
Solutions:
- CT: Use portal phase (best contrast between liver and lesions)
- MRI: Fat-suppressed T2, diffusion-weighted imaging (unaffected by fat)
- Both: Hepatocyte phase (metastases dark, enhancing liver bright)
”Technical Point: In fatty liver, diffusion-weighted imaging is particularly valuable because it's unaffected by fat. Metastases restrict diffusion (bright DWI), while fatty liver does not, maintaining high lesion conspicuity.
Source: European Journal of Radiology - Liver Metastasis Detection in Steatotic Liver: CT vs. MRI Date: 2021
Cirrhosis: Diagnostic Challenges
Challenges:
- Regenerative nodules: Can mimic metastases on CT
- Dysplastic nodules: Can mimic metastases
- HCC: Primary liver cancer is concern, not metastasis
MRI Advantages:
- Hepatocyte phase: Regenerative nodules enhance (contain hepatocytes), metastases do not
- Diffusion-weighted imaging: Helps distinguish malignant from benign
- Multiphasic imaging: Characterizes nodules typical of HCC
”Clinical Scenario: In patients with cirrhosis, liver lesions are more likely to be HCC or dysplastic nodules than metastases. MRI with hepatocyte-specific contrast is essential for this differentiation.
Source: Hepatology - Liver Lesions in Cirrhosis: MRI for Differentiation Date: 2022
Indeterminate Lesions: Characterization
Common Benign Mimics
Lesions That Mimic Metastases:
| Lesion | CT Appearance | MRI Appearance | Key Differentiator |
|---|---|---|---|
| Hemangioma | Hypoattenuating, may mimic mets | T2 very bright, peripheral nodular enhancement with centripetal fill-in | T2 very bright, centripetal fill-in, hepatocyte phase iso- or hyperintense |
| Cyst | Hypoattenuating, water attenuation | T1 dark, T2 very bright, no enhancement | No enhancement, water signal on all sequences |
| Focal nodular hyperplasia (FNH) | Hyperenhancing arterial, may mimic hypervascular mets | Arterial hyperenhancement, hepatocyte phase hyperintense (contains hepatocytes) | Hepatocyte phase bright (vs. mets dark), central scar |
| Hepatic adenoma | Hyperenhancing arterial, may mimic hypervascular mets | Arterial hyperenhancement, hepatocyte phase variable | Clinical context (oral contraceptives), hepatocyte phase variable |
| Perfusional pseudo-lesion | Focal hypoattenuation, may mimic mets | May appear as T2 bright, ill-defined | No mass effect, characteristic location (focal fatty sparing) |
”Characterization Challenge: Up to 30% of liver lesions found on cancer staging CTs are benign (hemangiomas, cysts). MRI with hepatocyte-specific contrast can characterize >90% of these indeterminate lesions, preventing misdiagnosis and inappropriate treatment.
Source: Radiographics - Indeterminate Liver Lesions on CT: MRI Characterization Date: 2021
MRI Characterization Algorithm
Stepwise Approach:
- T2-weighted: Very bright? → Cyst or hemangioma
- Diffusion-weighted: Restricted? → Mets or malignant; No restriction? → Benign
- Arterial phase: Peripheral nodular enhancement? → Hemangioma
- Hepatocyte phase: Hyperintense? → FNH, adenoma, HCC; Hypointense? → Metastasis
- Clinical context: Known primary cancer, cirrhosis, oral contraceptives
”Diagnostic Algorithm: This stepwise MRI approach characterizes >90% of indeterminate liver lesions. Lesions that remain indeterminate after MRI may require biopsy or short-interval follow-up (3 months) to assess stability.
Source: American Journal of Roentgenology - Algorithmic Approach to Indeterminate Liver Lesions Date: 2023
Patient Guide: What to Expect
During Your Imaging
CT Scan:
- Preparation: No food/drink 4 hours before (if contrast planned)
- IV placement: Required for IV contrast
- Contrast: Warm flushing sensation
- Breath-hold: May be asked to hold breath briefly
- Duration: 5-10 minutes
- After: Resume normal activities; hydrate to clear contrast
MRI Scan:
- Preparation: No special preparation (remove metal)
- IV placement: Required for gadolinium contrast
- Positioning: Lie on table, abdomen coil positioned
- Contrast: Cooler sensation than CT contrast
- Breath-hold: Multiple breath-holds (15-20 seconds each)
- Duration: 30-45 minutes
- Noise: Loud tapping noises (earplugs provided)
- After: Resume normal activities; gadolinium clears within 24 hours
Questions Patients Commonly Ask
Q: Can liver metastases be missed on CT scan?
A: Yes, CT misses 20-30% of liver metastases ＜1 cm. For patients being considered for curative liver surgery, MRI is essential to ensure accurate staging. For patients on systemic therapy (not surgical candidates), CT detection of lesions >1 cm is usually sufficient.
Q: Will I need both CT and MRI?
A: Not necessarily. For most patients, CT alone is adequate. MRI is added when surgical resection is considered, when CT shows indeterminate lesions, or for high-risk tumors (colon, breast, neuroendocrine) where finding small metastases changes management.
Q: Which test is more accurate for liver metastases?
A: MRI is more sensitive (detects more lesions, especially ＜1 cm) and provides better characterization of indeterminate lesions. However, CT is faster, cheaper, and provides whole-body staging. The "better" test depends on the clinical question.
Q: Does having liver metastases mean my cancer is incurable?
A: Not necessarily. Isolated liver metastases from colorectal cancer, neuroendocrine tumors, and some other cancers can be surgically resected with curative intent. Accurate imaging (CT + MRI) is essential to determine resectability.
Q: How often will I need repeat liver imaging?
A: Depends on treatment. On systemic therapy, repeat imaging every 2-3 months assesses treatment response. After liver-directed therapy (ablation, resection), imaging every 3-6 months monitors for recurrence. MRI is preferred for follow-up if liver-directed therapy was used.
Q: Can liver metastases be treated?
A: Yes. Treatment options include surgical resection (curative for limited disease), thermal ablation (RFA, MWA, cryoablation), transarterial therapies (TACE, Y90), stereotactic radiation (SBRT), and systemic therapy (chemotherapy, targeted therapy, immunotherapy). Imaging determines which options are feasible.
Key Takeaways: Liver Metastases Imaging
-
CT is first-line: Contrast-enhanced CT (portal venous phase) detects >80% of liver metastases >1 cm and provides whole-body staging in a single exam. CT is adequate for most patients undergoing systemic therapy.
-
MRI for small lesions: MRI detects 70-80% of metastases ＜5 mm (vs. 30-50% for CT) and 80-90% of 5-10 mm lesions (vs. 50-70% for CT). This superior sensitivity is critical for surgical candidates where missing even a small lesion precludes cure.
-
MRI characterizes indeterminate lesions: Up to 30% of liver lesions on cancer staging CTs are benign (hemangiomas, cysts). MRI with hepatocyte-specific contrast characterizes >90% of these indeterminate lesions, preventing misdiagnosis.
-
Hepatocyte phase is key: On hepatocyte-specific contrast MRI, metastases appear dark (no hepatocytes) while benign lesions with hepatocytes (FNH, adenoma, HCC) appear bright. This single finding characterizes many indeterminate CT lesions.
-
Surgical candidacy matters: If liver metastases are potentially resectable (curative intent), MRI is essential to ensure accurate staging. If systemic therapy only is planned (palliative), CT alone is usually sufficient.
-
Primary cancer guides approach: Colorectal, breast, and neuroendocrine cancers have high prevalence of liver mets—MRI is often indicated. For other cancers, CT alone is usually adequate unless indeterminate lesions or surgical candidacy.
-
Liver-directed therapy requires MRI: For ablation, embolization, SBRT, or surgical resection, MRI provides precise lesion mapping needed for treatment planning. MRI ensures no additional small metastases are missed that would compromise treatment success.
-
Diffusion-weighted imaging adds value: DWI detects small metastases invisible on other sequences and helps distinguish malignant (restricted diffusion) from benign (no restriction) lesions. DWI is particularly valuable in fatty liver where other sequences may be degraded.
”Clinical Bottom Line: CT is the first-line test for liver metastasis detection in most cancer patients. MRI is essential for surgical candidates, those with indeterminate lesions on CT, and high-risk primaries (colon, breast, neuroendocrine) where detecting small metastases changes management. The key is matching imaging intensity to clinical intent—curative surgery requires maximal sensitivity (MRI), while palliative systemic therapy often requires only CT.
References & Further Reading
- American College of Radiology. ACR Appropriateness Criteria®®: Liver Metastases. 2023.
- Annals of Surgical Oncology. "Impact of Liver MRI on Surgical Management of Colorectal Liver Metastases." 2021.
- Radiographics. "CT of Liver Metastases: Protocol and Interpretation." 2021.
- Radiographics. "Liver MRI: Hepatocyte-Specific Contrast Agents." 2022.
- European Journal of Radiology. "CT vs. MRI for Liver Metastasis Detection in Colorectal Cancer." 2022.
- Journal of Clinical Oncology. "Impact of Preoperative MRI on Outcomes After Liver Resection for Metastases." 2023.
This article was independently researched and written based on current hepatobiliary imaging guidelines and peer-reviewed literature. It emphasizes CT as the first-line test for most patients while recognizing MRI's essential role in surgical candidates and for characterizing indeterminate lesions.